The etiopathogenesis of amyotrophic lateral sclerosis (ALS) remains contentious, but new findings related to mutations of the Cu, Zn-superoxide dismutase (SOD1) gene continue to provide crucial insights. Using a conformation-specific antibody that detects misfolded SOD1 (C4F6), Bosco et al. () recently reported that oxidized wild-type SOD1 and mutant SOD1 share a conformational epitope that is not present in normal wild-type SOD1, but present in a subset of sporadic ALS (SALS) cases. Recombinant, oxidized wild-type SOD1 and wild-type SOD1 immunopurified from SALS tissues inhibited axonal transport in a manner similar to that of familial ALS (FALS)-linked mutant SOD1 (Bosco et al., ), indicating that wild-type SOD1 might develop a pathogenic modification even in SALS cases. The authors noted that a specific SOD1 residue, Cys111, was critical for the pathological C4F6 epitope (Bosco et al., ). This report carries added significance because it overlaps with recent observations about copper interactions in ALS pathogenesis that implicate the same residue in oxidized SOD1.
Since SOD1 is a major Cu-binding protein, and since Cu can be harmfully pro-oxidant, considerable research has explored whether aberrant Cu biochemistry could underlie FALS pathogenesis. Indeed, pharmacological and genetic interventions that lower intracellular Cu partly rescue the FALS phenotype in mutant SOD1 transgenic mice (Hottinger et al., ; Nagano et al., , ; Kiaei et al., ; Tokuda et al., ). Conversely, overexpression of the Cu-chaperone of SOD1 (CCS), which presents Cu to SOD1, worsens the FALS phenotype in double CCS/mutant SOD1 transgenic mice (Son et al., ). On the other hand, the FALS phenotype was not affected by genetic deletion of CCS (CCS knockout mice crossed with mutant SOD1 mice; Subramaniam et al., ). Also, active site copper was effectively eliminated from the pathogenic reaction via amino acid substitutions that disrupt copper binding but do not eliminate toxicity, and pathogenic mutant SOD1 mice express normally active and normally metallated dimeric SOD1 (Lelie et al., ).
The critical Cys111 of pathogenic SOD1 described by Bosco et al. () may reconcile the evidence implicating Cu with the evidence supporting pathogenic SOD1 instability, by supporting the possibility that ectopic binding of Cu outside the active site could contribute to pathogenesis (Liu et al., ). Immobilized Cu affinity chromatography resolves FALS-mutant SOD1 into an abnormal high-affinity fraction, termed SOD1HAC (Watanabe et al., ). SOD1HAC was observed for all pathogenic SOD1 mutants whether expressed in yeast, mammalian cell culture, or transgenic mouse spinal cords (Watanabe et al., ). SOD1HAC could be generated from wild-type SOD1 by Cys111 oxidation with GSNO or hydrogen peroxide, which induced SOD1 monomerization. Covalent cross-linking of mutant SOD1 prevented such monomerization (Kishigami et al., ), consistent with monomerization of SOD1 being necessary for the formation of the adventitial high-affinity Cu-binding site on SOD1HAC. While the precise site is not clear, ectopic Cu binding to SOD1HAC gains redox-activity.(Kishigami et al., ).
Mutant SOD1 is more susceptible to intramolecular disulfide reduction (Tiwari and Hayward, ). This renders the critical Cys111 vulnerable to modification by GSNO or peroxide that could induce monomerization and SOD1HAC formation, consistent with the hypothesis that SOD1 is dissociated into a potentially toxic SOD1HAC monomer when Cys111 is targeted by oxidative stress products like GSNO or H2O2, an event of increased likelihood in SOD1 mutants. Cys111 modification appears to disrupt the contact of the dimer interface between subunits. The finding that C111S substitution decreased SOD1HAC in mutant SOD1 (Watanabe et al., ) supports this contention. A similar cysteine-mediated conformational change has been reported for transthyretin, whose mutations cause familial amyloid polyneuropathy. Modification of a cysteine residue in transthyretin was shown to decrease tetramer stability, thereby generating monomer that subsequently formed amyloid (Zhang and Kelly, , ). The findings of Bosco et al. (), who demonstrated that oxidation of Cys111 mediated the pathogenic properties of SOD1, would be consistent with a similar pathogenic mechanism, and explain why dimeric forms of SOD1 mutants may not be the primary toxic species (Lelie et al., ).
References
1
BoscoD. A.MorfiniG.KarabacakN. M.SongY.Gros-LouisF.PasinelliP.GoolsbyH.FontaineB. A.LemayN.McKenna-YasekD.FroschM. P.AgarJ. N.JulienJ. P.BradyS. T.BrownR. H.Jr. (2010). Wild-type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS. Nat. Neurosci.13, 1396–1403.10.1038/nn.2660
2
HottingerA. F.FineE. G.GurneyM. E.ZurnA. D.AebischerP. (1997). The copper chelator d-penicillamine delays onset of disease and extends survival in a transgenic mouse model of familial amyotrophic lateral sclerosis. Eur. J. Neurosci.9, 1548–1551.10.1111/j.1460-9568.1997.tb01511.x
3
KiaeiM.BushA. I.MorrisonB. M.MorrisonJ. H.ChernyR. A.VolitakisI.BealM. F.GordonJ. W. (2004). Genetically decreased spinal cord copper concentration prolongs life in a transgenic mouse model of amyotrophic lateral sclerosis. J. Neurosci.24, 7945–7950.10.1523/JNEUROSCI.2000-04.2004
4
KishigamiH.NaganoS.BushA. I.SakodaS. (2010). Monomerized Cu, Zn-superoxide dismutase induces oxidative stress through aberrant Cu binding. Free Radic. Biol. Med.48, 945–952.10.1016/j.freeradbiomed.2010.01.008
5
LelieH. L.LibaA.BourassaM. W.ChattopadhyayM.ChanP. K.GrallaE. B.MillerL. M.BorcheltD. R.ValentineJ. S.WhiteleggeJ. P. (2011). Copper and zinc metallation status of copper-zinc superoxide dismutase from ALS-transgenic mice. J. Biol. Chem.286, 2795–2806.10.1074/jbc.M110.186999
6
LiuH.ZhuH.EggersD. K.NersissianA. M.FaullK. F.GotoJ. J.AiJ.Sanders-LoehrJ.GrallaE. B.ValentineJ. S. (2000). Copper(2+) binding to the surface residue cysteine 111 of His46Arg human copper-zinc superoxide dismutase, a familial amyotrophic lateral sclerosis mutant. Biochemistry39, 8125–8132.10.1021/bi0009441
7
NaganoS.FujiiY.YamamotoT.TaniyamaM.FukadaK.YanagiharaT.SakodaS. (2003). The efficacy of trientine or ascorbate alone compared to that of the combined treatment with these two agents in familial amyotrophic lateral sclerosis model mice. Exp. Neurol.179, 176–180.10.1016/S0014-4886(02)00014-6
8
NaganoS.OgawaY.YanagiharaT.SakodaS. (1999). Benefit of a combined treatment with trientine and ascorbate in familial amyotrophic lateral sclerosis model mice. Neurosci. Lett.265, 159–162.10.1016/S0304-3940(99)00227-X
9
SonM.PuttaparthiK.KawamataH.RajendranB.BoyerP. J.ManfrediG.ElliottJ. L. (2007). Overexpression of CCS in G93A-SOD1 mice leads to accelerated neurological deficits with severe mitochondrial pathology. Proc. Natl. Acad. Sci. U.S.A.104, 6072–6077.10.1073/pnas.0610923104
10
SubramaniamJ. R.LyonsW. E.LiuJ.BartnikasT. B.RothsteinJ.PriceD. L.ClevelandD. W.GitlinJ. D.WongP. C. (2002). Mutant SOD1 causes motor neuron disease independent of copper chaperone-mediated copper loading. Nat. Neurosci.5, 301–307.10.1038/nn823
11
TiwariA.HaywardL. J. (2003). Familial amyotrophic lateral sclerosis mutants of copper/zinc superoxide dismutase are susceptible to disulfide reduction. J. Biol. Chem.278, 5984–5992.10.1074/jbc.M210419200
12
TokudaE.OnoS.IshigeK.WatanabeS.OkawaE.ItoY.SuzukiT. (2008). Ammonium tetrathiomolybdate delays onset, prolongs survival, and slows progression of disease in a mouse model for amyotrophic lateral sclerosis. Exp. Neurol.213, 122–128.10.1016/j.expneurol.2008.05.011
13
WatanabeS.NaganoS.DuceJ.KiaeiM.LiQ. X.TuckerS. M.TiwariA.BrownR. H.Jr.BealM. F.HaywardL. J.CulottaV. C.YoshiharaS.SakodaS.BushA. I. (2007). Increased affinity for copper mediated by cysteine 111 in forms of mutant superoxide dismutase 1 linked to amyotrophic lateral sclerosis. Free Radic. Biol. Med.42, 1534–1542.10.1016/j.freeradbiomed.2007.02.004
14
ZhangQ.KellyJ. W. (2003). Cys10 mixed disulfides make transthyretin more amyloidogenic under mildly acidic conditions. Biochemistry42, 8756–8761.10.1021/bi034219c
15
ZhangQ.KellyJ. W. (2005). Cys-10 mixed disulfide modifications exacerbate transthyretin familial variant amyloidogenicity: a likely explanation for variable clinical expression of amyloidosis and the lack of pathology in C10S/V30M transgenic mice?Biochemistry44, 9079–9085.10.1021/bi050585f
Summary
Keywords
Amyotrophic Lateral Sclerosis, Copper, neurodegeneration, Superoxide Dismutase
Citation
Bush AI (2011) A Copper Binding Site within the Pathological Conformer Epitope of Mutant SOD1. Front. Neurosci. 5:97. doi: 10.3389/fnins.2011.00097
Received
14 May 2011
Accepted
20 July 2011
Published
11 August 2011
Volume
5 - 2011
Copyright
© 2011 Bush.
This is an open-access article subject to a non-exclusive license between the authors and Frontiers Media SA, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and other Frontiers conditions are complied with.
*Correspondence: a.bush@mhri.edu.au
This article was submitted to Frontiers in Neurodegeneration, a specialty of Frontiers in Neuroscience.
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.